Point72 Asset Management L.P. Sells 103,084 Shares of Glaukos Co. (NYSE:GKOS)

Point72 Asset Management L.P. cut its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 26.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 280,312 shares of the medical instruments supplier's stock after selling 103,084 shares during the period. Point72 Asset Management L.P. owned 0.51% of Glaukos worth $42,030,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. ProShare Advisors LLC raised its position in shares of Glaukos by 44.0% in the 4th quarter. ProShare Advisors LLC now owns 14,869 shares of the medical instruments supplier's stock worth $2,229,000 after acquiring an additional 4,542 shares in the last quarter. Nicholas Investment Partners LP grew its stake in Glaukos by 54.2% during the fourth quarter. Nicholas Investment Partners LP now owns 31,961 shares of the medical instruments supplier's stock worth $4,792,000 after purchasing an additional 11,237 shares during the period. Nuveen Asset Management LLC increased its holdings in Glaukos by 0.9% in the fourth quarter. Nuveen Asset Management LLC now owns 314,963 shares of the medical instruments supplier's stock worth $47,226,000 after purchasing an additional 2,665 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Glaukos by 3.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,349 shares of the medical instruments supplier's stock valued at $4,551,000 after buying an additional 984 shares during the period. Finally, Lazard Asset Management LLC lifted its stake in Glaukos by 228.2% in the fourth quarter. Lazard Asset Management LLC now owns 13,911 shares of the medical instruments supplier's stock valued at $2,085,000 after buying an additional 9,673 shares during the period. Institutional investors and hedge funds own 99.04% of the company's stock.

Insider Buying and Selling at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.80% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on GKOS shares. Mizuho reduced their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday, April 16th. Stephens reduced their price target on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Piper Sandler dropped their price objective on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. Truist Financial reissued a "buy" rating and set a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Finally, Morgan Stanley decreased their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Stock Up 0.3%

NYSE GKOS traded up $0.31 during trading hours on Monday, hitting $95.78. The company's stock had a trading volume of 782,401 shares, compared to its average volume of 687,917. The company has a market capitalization of $5.47 billion, a PE ratio of -33.37 and a beta of 0.83. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 52 week low of $77.10 and a 52 week high of $163.71. The company's 50-day simple moving average is $93.76 and its two-hundred day simple moving average is $125.61.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. The company's quarterly revenue was up 24.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.70) earnings per share. Research analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.